Ausgabe 2/2007
Special Issue: “Economic Evaluation in Health Care”
Inhalt (13 Artikel)
Pharmacoeconomic studies in Italy: a critical review of the literature
D. Cornago, L. Li Bassi, P. De Compadri, L. Garattini
The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
Vesna Bjegovic, Zorica Terzic, Jelena Marinkovic, Nebojsa Lalic, Sandra Sipetic, Ulrich Laaser
Patients’ willingness to pay for electronic communication with their general practitioner
Trine Strand Bergmo, Silje Camilla Wangberg
Systematic review of economic evaluations and cost analyses of guideline implementation strategies
Luke Vale, Ruth Thomas, Graeme MacLennan, Jeremy Grimshaw
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
Maureen P. M. H. Rutten-van Mölken, Jan B. Oostenbrink, Marc Miravitlles, Brigitta U. Monz
The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
Richard P. A. Norman, D. Gareth Evans, Douglas F. Easton, Kenneth C. Young
Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
K. Le Lay, E. Myon, S. Hill, L. Riou-Franca, D. Scott, M. Sidhu, D. Dunlop, R. Launois
An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
Sara K. Sheriff, K. Ulrich Petry, Hans Ikenberg, Geoffrey Crouse, Peter D. Mazonson, Christopher C. Santas
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
Andrew J. Palmer, William J. Valentine, Joshua A. Ray, Stephane Roze, Noemi Muszbek
Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
Livio Garattini
Discussion point: should governments buy drug patents?
Juan del Llano